In our study only few patients had elevated IL-6 and YKL-40 compared to historical healthy controls indicating that systemic IL-6 and YKL-40 levels may not be key mediators in glioma-associated systemic immune modulation at time of surgery or that individual changes are more important than the absolute plasma concentration. This evidence concerns the gene IL6 and central nervous system cancer.